Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18

Summary

Complement component C3 has a potential role in thrombotic pathologies. It is transformed, without proteolytic cleavage, into C3(H₂O) upon binding to the surface of activated platelets. We hypothesise that C3(H₂O) bound to activated platelets and to platelet-derived microparticles (PMPs) contributes to platelet-PMN complex (PPC) formation and to the binding of PMPs to PMNs. PAR-1 activation of platelets in human whole blood from normal individuals induced the formation of CD16⁺/CD42a⁺ PPC. The complement inhibitor compstatin and a C5a receptor antagonist inhibited PPC formation by 50 %, while monoclonal antibodies to C3(H₂O) or anti-CD11b inhibited PPC formation by 75–100 %. Using plasma protein-depleted blood and blood from a C3-deficient patient, we corroborated the dependence on C3, obtaining similar results after reconstitution with purified C3. By analogy with platelets, PMPs isolated from human serum were found to expose C3(H₂O) and bind to PMNs. This interaction was also blocked by the anti-C3(H₂O) and anti-CD11b monoclonal antibodies, indicating that C3(H₂O) and CD11b are involved in tethering PMPs to PMNs. We confirmed the direct interaction between C3(H₂O) and CD11b by quartz crystal microbalance analysis using purified native C3 and recombinant CD11b/CD18 and by flow cytometry using PMP and recombinant CD11b. Transfectants expressing CD11b/CD18 were also shown to specifically adhere to surface-bound C3(H₂O). We have identified contact-activated C3(H₂O) as a novel ligand for CD11b/CD18 that mediates PPC formation and the binding of PMPs to PMNs. Given the various roles of C3 in thrombotic reactions, this finding is likely to have important pathophysiological implications.

Keywords

Complement C3 - platelets - microparticles - PMN - platelet-leukocyte complex

• References

• 1 Cerletti C, Tamburrelli C, Izzi B. et al. Platelet-leukocyte interactions in thrombosis. Thromb Res 2012; 129: 263-266.
• 2 Lappegard KT, Garred P, Jonasson L. et al. A vital role for complement in heart disease. Mol Immunol 2014; 61: 126-134.
• 3 Samarkos M, Mylona E, Kapsimali V. The role of complement in the antiphospholipid syndrome: a novel mechanism for pregnancy morbidity. Semin Arthritis Rheum 2012; 42: 66-69.
• 4 Engstrom G, Hedblad B, Janzon L. et al. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur J Cardiovasc Preven Rehab 2007; 14: 392-397.
• 5 Palikhe A, Sinisalo J, Seppanen M. et al. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol 2007; 99: 890-895.
• 6 Polley MJ, Nachman R. The human complement system in thrombin-mediated platelet function. J Exp Med 1978; 147: 1713-1726.
• 7 Del Conde I, Cruz MA, Zhang H. et al. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201: 871-879.
• 8 Hamad OA, Nilsson PH, Wouters D. et al. Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol 2010; 184: 2686-2692.
• 9 Peerschke EI, Yin W, Grigg SE. et al. Blood platelets activate the classical pathway of human complement. J Thromb Haemost 2006; 04: 2035-2042.
• 10 Saggu G, Cortes C, Emch HN. et al. Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O). J Immunol 2013; 190: 6457-6467.
• 11 Bauer EM, Zheng H, Comhair S. et al. Complement C3 deficiency attenuates chronic hypoxia-induced pulmonary hypertension in mice. PloS one 2011; 06: e28578.
• 12 Gushiken FC, Han H, Li J. et al. Abnormal platelet function in C3-deficient mice. J Thromb Haemost 2009; 07: 865-870.
• 13 Darbousset R, Delierneux C, Mezouar S. et al. P2X1 expressed on polymorpho-nuclear neutrophils and platelets is required for thrombosis in mice. Blood 2014; 124: 2575-2585.
• 14 Darbousset R, Thomas GM, Mezouar S. et al. Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. Blood 2012; 120: 2133-2143.
• 15 Eltzschig HK, Macmanus CF, Colgan SP. Neutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface. Trends Cardiovasc Med 2008; 18: 103-107.
• 16 Massberg S, Grahl L, von Bruehl ML. et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nature Med 2010; 16: 887-896.
• 17 Langer HF, Chavakis T. Leukocyte-endothelial interactions in inflammation. J Cell Mol Med 2009; 13: 1211-1220.
• 18 Simon DI. Inflammation and vascular injury: basic discovery to drug development. Circ J 2012; 76: 1811-1818.
• 19 von Hundelshausen P, Koenen RR, Weber C. Platelet-mediated enhancement of leukocyte adhesion. Microcir 2009; 16: 84-96.
• 20 von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.
• 21 Siddiqui FA, Desai H, Amirkhosravi A. et al. The presence and release of tissue factor from human platelets. Platelets 2002; 13: 247-253.
• 22 Yin W, Ghebrehiwet B, Peerschke EI. Expression of complement components and inhibitors on platelet microparticles. Platelets 2008; 19: 225-233.
• 23 Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008; 111: 5271-5281.
• 24 Ghasemzadeh M, Hosseini E. Platelet-leukocyte crosstalk: Linking proinflammatory responses to procoagulant state. Thromb Res 2013; 131: 191-197.
• 25 Ehlers R, Ustinov V, Chen Z. et al. Targeting platelet-leukocyte interactions: identification of the integrin Mac-1 binding site for the platelet counter receptor glycoprotein Ibalpha. J Exp Med 2003; 198: 1077-1088.
• 26 Simon DI, Chen Z, Xu H. et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). The J Exp Med 2000; 192: 193-204.
• 27 Chavakis T, Santoso S, Clemetson KJ. et al. High molecular weight kininogen regulates platelet-leukocyte interactions by bridging Mac-1 and glycoprotein Ib. J Biol Chem 2003; 278: 45375-45381.
• 28 Santoso S, Sachs UJ, Kroll H. et al. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med 2002; 196: 679-691.
• 29 Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J Clin Invest 1997; 100: 2085-2093.
• 30 Patko Z, Csaszar A, Acsady G. et al. Roles of Mac-1 and glycoprotein IIb/IIIa integrins in leukocyte-platelet aggregate formation: stabilization by Mac-1 and inhibition by GpIIb/IIIa blockers. Platelets 2012; 23: 368-375.
• 31 Hamad OA, Ekdahl KN, Nilsson PH. et al. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost 2008; 06: 1413-14121.
• 32 Lood C, Eriksson S, Gullstrand B. et al. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus--a possible link to venous thrombosis?. Lupus 2012; 21: 1423-1432.
• 33 Pekna M, Nilsson L, Nilsson-Ekdahl K. et al. Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction. Clin Exp Immunol 1993; 91: 404-409.
• 34 Schwendinger MG, Spruth M, Schoch J. et al. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells. J Immunol 1997; 158: 5455-5463.
• 35 Alaei S, Larcher C, Ebenbichler C. et al. Isolation and biochemical characterization of the iC3b receptor of Candida albicans. Infect Immun 1993; 61: 1395-1399.
• 36 Ross GD, Newman SL, Lambris JD. et al. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin. J Exp Med 1983; 334-352.
• 37 Orlova VV, Choi EY, Xie C. et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 2007; 26: 1129-1139.
• 38 Andersson J, Ekdahl KN, Larsson R. et al. C3 adsorbed to a polymer surface can form an initiating alternative pathway convertase. J Immunol 2002; 168: 5786-5791.
• 39 Janssen BJ, Huizinga EG, Raaijmakers HC. et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005; 437: 505-511.
• 40 de Gaetano G, Cerletti C, Evangelista V. Recent advances in platelet-polymorphonuclear leukocyte interaction. Haemostasis 1999; 29: 41-49.
• 41 Shimaoka M, Shifman JM, Jing H. et al. Computational design of an integrin I domain stabilized in the open high affinity conformation. Nature Strucr Biol 2000; 07: 674-678.
• 42 Nilsson B, Nilsson Ekdahl K. The tick-over theory revisited: is C3 a contact-activated protein?. Immunobiol 2012; 217: 1106-1110.
• 43 Klapper Y, Hamad OA, Teramura Y. et al. Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles. Biomaterials 2014; 35: 3688-3696.
• 44 Nilsson B, Nilsson UR. SDS denaturation of complement factor C3 as a model for allosteric modifications occurring during C3b binding: demonstration of a profound conformational change by means of circular dichroism and quantitative immunoprecipitation. Immunol Lett 1986; 13: 11-14.
• 45 Osterud B, Bjorklid E. Tissue factor in blood cells and endothelial cells. Front Biosci 2012; 04: 289-299.